GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL BTA) » Definitions » Cyclically Adjusted PB Ratio

PharmaLundensis AB (XSAT:PHAL BTA) Cyclically Adjusted PB Ratio : (As of Jun. 08, 2024)


View and export this data going back to . Start your Free Trial

What is PharmaLundensis AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


PharmaLundensis AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PharmaLundensis AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB Cyclically Adjusted PB Ratio Chart

PharmaLundensis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.12 2.00 2.20 1.62 1.14

PharmaLundensis AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.76 1.06 1.14 1.89

Competitive Comparison of PharmaLundensis AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, PharmaLundensis AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Cyclically Adjusted PB Ratio falls into.



PharmaLundensis AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PharmaLundensis AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, PharmaLundensis AB's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.124/132.2054*132.2054
=0.124

Current CPI (Mar. 2024) = 132.2054.

PharmaLundensis AB Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.505 100.432 0.665
201409 0.425 100.161 0.561
201412 0.670 100.225 0.884
201503 0.631 99.950 0.835
201506 0.582 99.995 0.769
201509 0.514 100.228 0.678
201512 0.872 100.276 1.150
201603 0.840 100.751 1.102
201606 0.757 101.019 0.991
201609 0.694 101.138 0.907
201612 0.640 102.022 0.829
201703 1.062 102.022 1.376
201706 0.965 102.752 1.242
201709 0.882 103.279 1.129
201712 0.450 103.793 0.573
201803 0.383 103.962 0.487
201806 0.450 104.875 0.567
201809 0.383 105.679 0.479
201812 0.454 105.912 0.567
201903 0.382 105.886 0.477
201906 0.418 106.742 0.518
201909 0.352 107.214 0.434
201912 0.360 107.766 0.442
202003 0.314 106.563 0.390
202006 0.255 107.498 0.314
202009 0.220 107.635 0.270
202012 0.173 108.296 0.211
202103 0.300 108.360 0.366
202106 0.257 108.928 0.312
202109 0.219 110.338 0.262
202112 0.188 112.486 0.221
202203 0.114 114.825 0.131
202206 0.182 118.384 0.203
202209 0.145 122.296 0.157
202212 0.103 126.365 0.108
202303 0.232 127.042 0.241
202306 0.174 129.407 0.178
202309 0.111 130.224 0.113
202312 0.186 131.912 0.186
202403 0.124 132.205 0.124

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PharmaLundensis AB  (XSAT:PHAL BTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PharmaLundensis AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB (XSAT:PHAL BTA) Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 2, Lund, SWE, 22381
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL BTA) Headlines

No Headlines